TG Therapeutics (TGTX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.35
- Estimate
- $0.26
- Surprise
- +35.9%
- Revenue (period 2026-09-30)
- $259.9M
- Score at report (before → after)
- 5.5 → 6.3/10
Revenue source: xbrl.
How the report landed
TG Therapeutics (TGTX) beat the $0.26 estimate with adjusted EPS of $0.35 — a large 35.9% upside surprise. TrendMatrix's engine moved from Hold (5.5/10) to Sell at 6.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TGTX Sell at 6.1/10.
1 of the last 4 quarters beat the estimate; this quarter's +35.9% surprise compares with a -36.3% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: BRIUMVI
- Concentration risk — Supplier: sole-source CMO/API suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $65.78
- Stop
- $61.18
The stock trades at 94.6× trailing but 22.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 78 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
TGTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.70B
- P/E (fwd)
- 22.0
- P/E (ttm)
- 94.6
- 52-week range
- $26.76–$63.60
- Off 52-week high
- -3.4%
- RSI (14)
- 78
- Volume vs avg
- 0.74×
- Score today
- 6.1/10